首页> 外文期刊>Langenbeck's archives of surgery >Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.
【24h】

Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

机译:病原学基因改变对甲状腺乳头状癌预后的影响。 ESES维也纳演示文稿。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: BRAF mutations and RET or NTRK1 rearrangements were identified as causing events that drive the malignant transformation of the thyroid follicular cell. The impact of these alterations on the course of papillary thyroid carcinoma (PTC) is still unsettled. PATIENTS AND METHODS: Tumor tissues of 290 (98 male, 192 female) patients were intra-operatively snap frozen or harvested from archival paraffin-embedded blocks and used for extraction of DNA and RNA. Comprehensive analysis of RET/PTC and NTRK1 rearrangements was carried out by multiplex screening RT-PCR, hybrid-specific RT-PCR and sequencing of detected hybrids. A mutation-specific PCR was used for BRAF analysis. RESULTS: The BRAF V600E mutation was detected in 122/290 (42%), RET rearrangements in 20/137 (14.6%), and NTRK1 rearrangements in 15/93 (16.1%) PTCs. One hundred forty one out of 290 (48.6%) PTCs demonstrated none of the genetic alterations studied. Eight PTCs expressed two different mutations (1 RET/PTC + BRAF, 6 NTRK1 + BRAF, 1 RET/PTC + NTRK1). Tumor-specific survival analysis (mean follow-up, 5.5 years) demonstrated no significant difference, but a tendency toward worse prognosis of BRAF-positive patients compared to BRAF-negative patients or rearrangement-positive patients, respectively. CONCLUSION: Long-term follow-up data on large tumor panels are needed to disclose significant survival differences of prognostic predictors on PTC. This study provides further evidence that patients harboring BRAF-V600E-positive PTCs may experience an unfavorable course of the disease compared to patients with tumors carrying other genetic alterations.
机译:引言:BRAF突变和RET或NTRK1重排被确定为引起甲状腺滤泡细胞恶性转化的事件。这些改变对甲状腺乳头状癌(PTC)病程的影响尚未解决。患者和方法:对290名患者(98名男性,192名女性)的肿瘤组织进行术中速冻或从存档石蜡包埋的块中收集,用于提取DNA和RNA。 RET / PTC和NTRK1重排的综合分析是通过多重筛选RT-PCR,杂交特异性RT-PCR以及对检测到的杂交体进行测序来进行的。突变特异性PCR用于BRAF分析。结果:在122/290(42%),20/137(14.6%)的RET重排和在15/93(16.1%)的PTCs中检测到NTRK1重排。在290个(48.6%)PTC中,有111个没有显示出所研究的遗传改变。八个PTC表示两个不同的突变(1个RET / PTC + BRAF,6个NTRK1 + BRAF,1个RET / PTC + NTRK1)。肿瘤特异性生存分析(平均随访期5.5年)显示无显着差异,但与BRAF阴性或重排阳性的患者相比,BRAF阳性患者的预后更差。结论:需要在大型肿瘤组上进行长期随访,以揭示PTC预后指标的显着生存差异。这项研究提供了进一步的证据,表明携带BRAF-V600E阳性PTC的患者与携带其他基因改变的肿瘤患者相比,可能会经历不利的病程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号